Study Objectives: Narcolepsy-cataplexy has long been thought to have an autoimmune origin. Although susceptibility to narcolepsy, like many autoimmune conditions, is largely genetically determined, environmental factors are involved based on the high discordance rate (approximately 75%) of monozygotic twins. This study evaluated whether Streptococcus pyogenes and Helicobacter pylori infections are triggers for narcolepsy.

Design: Retrospective, case-control.

Setting: Sleep centers of general hospitals.

Participants: 200 patients with narcolepsy/hypocretin deficiency, with a primary focus on recent onset cases and 200 age-matched healthy controls. All patients were DQB1*0602 positive with low CSF hypocretin-1 or had clear-cut cataplexy.

Measurements And Results: Participants were tested for markers of immune response to beta hemolytic streptococcus (anti-streptolysin O [ASO]; anti DNAse B [ADB]) and Helicobacter pylori [Anti Hp IgG], two bacterial infections known to trigger autoimmunity. A general inflammatory marker, C-reactive protein (CRP), was also studied. When compared to controls, ASO and ADB titers were highest close to narcolepsy onset, and decreased with disease duration. For example, ASO > or = 200 IU (ADB > or = 480 IU) were found in 51% (45%) of 67 patients within 3 years of onset, compared to 19% (17%) of 67 age matched controls (OR = 4.3 [OR = 4.1], P < 0.0005) or 20% (15%) of 69 patients with long-standing disease (OR = 4.0 [OR = 4.8], P < 0.0005]. CRP (mean values) and Anti Hp IgG (% positive) did not differ from controls.

Conclusions: Streptococcal infections are probably a significant environmental trigger for narcolepsy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717204PMC
http://dx.doi.org/10.1093/sleep/32.8.979DOI Listing

Publication Analysis

Top Keywords

narcolepsy onset
8
helicobacter pylori
8
patients
5
elevated anti-streptococcal
4
anti-streptococcal antibodies
4
antibodies patients
4
narcolepsy
4
patients narcolepsy
4
onset
4
onset study
4

Similar Publications

Narcolepsy type 1 (NT1) is a clinical syndrome defined by recurrent episodes of excessive daytime sleepiness (EDS), episodes of cataplexy, hypnagogic hallucinations, and sleep paralysis. Symptoms typically manifest in the second or third decade with another small peak in the fourth decade. In this report we describe the case of a 64-year-old woman presenting with new-onset visual hallucinations as the main complaint.

View Article and Find Full Text PDF

First Episode Psychosis in a Teen with Narcolepsy and Cataplexy.

Psychopharmacol Bull

January 2025

Abhishek Reddy, MD, Assistant Professor, Child and Adolescent Psychiatry, Sleep Medicine, Department of Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.

Article Synopsis
  • Narcolepsy with cataplexy (NT1) is a rare sleep disorder that can be linked to early-onset psychosis, particularly in kids and teens.
  • After excluding other medical issues, an adolescent girl with NT1 was initially diagnosed with a brief psychotic episode and treated with Risperidone.
  • Her symptoms improved significantly after switching to Chlorpromazine, marking one of the first successful uses of this drug for managing first-episode psychosis in a patient with NT1.
View Article and Find Full Text PDF

Objectives: To explore the efficacy of ofatumumab in new onset narcolepsy type 1 following SARS-CoV-2 infection.

Methods: We present a 9-year-old girl who experienced new onset narcolepsy type 1 following SARS-CoV-2 infection. Polysomnography (PSG) followed by a daytime multiple sleep latency test (MSLT) was under taken after admission.

View Article and Find Full Text PDF
Article Synopsis
  • Excessive daytime sleepiness can be a symptom of post-COVID syndrome and narcolepsy, a rare sleep disorder that may have an autoimmune cause.
  • A case study of a 25-year-old male showed he developed narcolepsy type II after COVID-19, confirmed through sleep tests and neuropsychological evaluations.
  • Treatment with high-dose corticosteroids led to an immediate improvement in his symptoms, suggesting that immunosuppressive therapy might be a viable option for managing narcolepsy following COVID-19.
View Article and Find Full Text PDF
Article Synopsis
  • Charles Fisher was a groundbreaking researcher in sleep medicine who made significant contributions in various areas of sleep study, particularly concerning REM sleep in narcoleptic patients.
  • He was the first to document several key concepts, such as the effects of benzodiazepines on night terrors and the connection between REM sleep and sexual arousal.
  • Collaborating with notable figures like William C. Dement, Fisher’s work laid a foundation for understanding sleep disorders, behaviors, and cycles, influencing the field well beyond his era.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!